

**AGENDA ITEM 05 – CHIEF EXECUTIVE’S REPORT
BOARD OF DIRECTORS 4 APRIL 2019**

Report title	Chief executive’s report
Report from	David Probert, chief executive
Prepared by	David Probert and the executive team
Link to strategic objectives	The chief executive’s report links to all eight strategic objectives

<p>Brief summary of report</p> <p>The report covers the following areas:</p> <ul style="list-style-type: none"> • CQC Report summary of outcome • Flu vaccination update • Awards and new appointments • Glaucoma Research • Finance • Oriel 					
<p>Action required/recommendation.</p> <p>The board is asked to note the chief executive’s report.</p>					
For assurance		For decision		For discussion	To note ✓

MOORFIELDS EYE HOSPITAL NHS FOUNDATION TRUST

PUBLIC BOARD MEETING – 4 APRIL 2019

Chief Executive's report

1. Quality

On 12 March 2019 the Care Quality Commission (CQC) published our **inspection report** and ratings. As the report sets out, we have made significant improvements since our previous CQC inspection in 2016. Every service that was inspected was rated as either 'good' or 'outstanding' and we received an overall trust rating of 'good'. Moorfields has received 'outstanding' ratings for:

- The effectiveness of the care and treatment and the outcomes we deliver across the whole trust,
- Surgical services at City Road, a reflection of our surgery being regarded internationally as world leading in many sub-specialty areas,
- Surgical services at Bedford,
- Caring at City Road.

The CQC also found several areas of outstanding practice, including:

- Patient outcomes in a number of specialties were better than the national and international standards.
- The trust's referral to treatment time for non-admitted pathways was consistently better than the England overall performance and we met or exceeded all national access targets.
- All staff cared for patients with compassion and care and treatment was responsive to the needs of patients. Each of the patients the CQC engaged with spoke highly of the caring attitude of staff.
- Services identified the care needed for specific patient groups and had strategies in place to care for patients with learning disabilities and dementia including a patient passport and 'this is me' documentation.
- Excellent emotional support and practical support was provided to patients experiencing sight loss including counselling and support to register for a certification of visual impairment.
- Our award winning #KnowYourDrops patient education campaign, led by our pharmacists, was recognised for helping patients to use eye drops correctly.
- Services participated in research projects, many with other ophthalmology providers, to drive improvement and identify best practice in care and treatment for patients.

I would like to extend my thanks to everyone for their hard work, commitment and dedication in preparing for the inspection and whilst hosting the CQC inspectors. Members of the executive team visited sites across the network to discuss the results with staff and celebrate what has been achieved. An action plan involving staff and teams across Moorfields is being developed to address the 19 points the CQC have raised that require actions. The report can be reviewed in detail using the following link: <https://www.cqc.org.uk/provider/RP6>

As reported last month, the trust achieved its **flu vaccination** target by the end of February 2019. The final total as of 31 March 2019 was 1,027 front line staff (and 1,390 of all staff groups) vaccinated (a total of 77%).

2. Financial

The trust reported a surplus of £0.59m in month against a plan of a £1.06m surplus, a £0.47m adverse variance to plan. The year to date position is a surplus of £8.61m, £3.34m favourable to plan. NHS income was behind plan by £0.42m in February, with adverse performance in particular in elective procedures and retinal injections. Year to date efficiency scheme performance now stands at £0.42m below plan, an adverse move of £0.19m in-month. The

forecast efficiencies outturn remains in line with previous forecasts at £1.33m adverse. The Trust continues to forecast achievement of the revised Control Total of a £6.7m surplus.

3. People

Moorfields staff have been recognised in a list of the most influential people in the world of ophthalmology. The **Ophthalmologist Power List 2019** honours 50 clinicians, scientists and engineers who have made a significant contribution to their field. Moorfields' nurse consultant Adam Mapani is the first nurse to ever feature on the prestigious list.

Congratulations to these Moorfields staff who feature:

- Alan Bird, honorary consultant ophthalmologist
- Declan Flanagan, consultant ophthalmologist,
- David (Ted) Garway-Heath, IGA professor of ophthalmology for glaucoma and allied studies
- Pearse Keane, consultant ophthalmologist and NIHR clinician scientist, UCL Institute of Ophthalmology
- Professor Sir Peng Tee Khaw, consultant ophthalmic surgeon and Director for the UK NIHR Biomedical Research Centre in ophthalmology
- Adam Mapani, nurse consultant
- John Marshall, Frost professor of ophthalmology and deputy director responsible for enterprise, Institute of Ophthalmology, University College London in association with Moorfields Eye Hospital
- Mariya Moosajee, consultant ophthalmologist
- Dawn Sim, director of telemedicine and consultant ophthalmologist

Professor Sobha Sivaprasad, consultant ophthalmologist, has won the **Syneos Health Site Appreciation award**. The award recognises Sobha and colleagues' contribution to the pan-European VIOLET study that investigates the efficacy and safety of three different aflibercept regimens in patients with diabetic macular oedema. Sobha and the team were highly commended for the project's high quality data, excellent focus on patient safety, strong teamwork and communication.

A number of **new appointments** have been made in **clinical support services** and I would like to welcome Kelly McKenzie, interim head of orthoptics, David Essex, head of life sciences and Azizur Rahman, chief biomedical scientist for the eye bank, to the team.

I am also pleased to report a number of **consultant appointments** this month and would like to welcome Mariepi Cylwik (Anaesthetist), Senthilkumar Vijayan (Anaesthetist) and George Voyatzis (Specialist in Cataract and Accident & Emergency) to their new roles.

4. Research

The results of **the ground breaking LiGHT study** were published last weekend in the Lancet, one of the most prestigious medical journals in the world. This study, the largest of its kind in the world, was led by Moorfields Consultant and UCL Reader Gus Gazzard and it showed that laser treatment was superior to eye drops in lowering eye pressure in glaucoma. This treatment could save the NHS up to £250 million a year if applied to all previously diagnosed patients. This trial received widespread media coverage and many commentators worldwide remarked that the results could change the treatment of glaucoma around the world, especially in developing countries. This study was supported by the NIHR National Institute for Health Research including the Moorfields NIHR Biomedical Research centre.

5. Strategy

Building on our **public consultation work on Oriel** over the last six months to listen, learn and gain feedback from patients and carers about our proposed move we are now holding a further series of discussion groups for patients, carers and residents to get further feedback on this proposal. These new sessions will seek views on how the proposal will affect individuals, how our services should improve and what people think of the potential challenges. The discussion groups will be held in March and April 2019 in Camden, Dartford, Ealing, Hemel Hempstead, Islington, Milton Keynes, Stratford and Waterloo.

We are also commencing work to listen and learn from protected groups to identify potential issues of equality associated with our proposed service change. We will be using a combination of proactive approaches, both written and face to face, working with national, regional and local groups. All of our engagement activity will be used to inform our proposals.

The pre consultation business case will be considered by a committee in common on 24 April. This is the final decision-making group that will determine whether the consultation can proceed.

David Probert
Chief Executive
April 2019